First Large Real-World Study of Oregon's Licensed Psilocybin Services Published

Researchers led by Oregon Health & Science University have published the first large peer-reviewed study of what actually happens to people who use Oregon’s state-licensed psilocybin service centres — one of the few systems in the world where adult psilocybin access is clearly legal. The observational study appeared in JAMA Network Open on 19 August 2026.

What the study reported

According to the university’s announcement and the published paper, the research team followed 346 adults who attended a single supervised psilocybin session at one of 24 licensed Oregon service centres between November 2024 and June 2026, with follow-up surveys at one week, one month and three months (90 per cent completed follow-up). Oregon’s system — approved by voters in 2020, operating since 2023 — allows adults aged 21 and over to take psilocybin under a licensed facilitator’s supervision without any prescription or diagnosis. The university says more than 20,000 people have used the services since launch.

The researchers reported that at one month, 91.5 per cent of participants described the experience as beneficial, and 64.9 per cent ranked it among the ten most meaningful experiences of their lives. At three months, the authors reported reductions in moderate-to-severe symptoms of depression, anxiety and post-traumatic stress, alongside improved wellbeing and life satisfaction. On safety, the paper reports that seven of the 346 participants described the experience as harmful at three months, that four first-time users experienced adverse behavioural reactions requiring medical attention, and that no serious physical health events were recorded. Lead author Dr Todd Korthuis told NPR: “The data has swayed me. These results are very reassuring.”

Important caveats

This was an uncontrolled observational study of people who chose — and paid, typically hundreds to thousands of US dollars — to use the services, not a clinical trial. There was no comparison group, outcomes were self-reported, and the researchers note participants were healthier overall than typical clinical-trial populations, with only about half reporting moderate-to-severe depression beforehand. The sample also skewed heavily toward white, college-educated and higher-income participants. Johns Hopkins researcher Dr Albert Garcia-Romeu, who was not involved in the study, told NPR: “I would say that we really can’t generalize based on this study that it’s going to be this safe.” These are attributed research findings, not evidence that any treatment works.

What this means for Australians

Oregon is one of the handful of jurisdictions this site treats as clearly legal for supervised adult psilocybin access, and this study is the first substantial peer-reviewed look at safety and outcomes inside that licensed system — directly relevant to Australians researching an Oregon service centre. It is a different model from Australia’s: here, psilocybin can only be prescribed by TGA-authorised psychiatrists for treatment-resistant depression, and outside that clinical pathway psilocybin remains illegal to possess or supply in every Australian state and territory. Psilocybin services are legal in Oregon, not in Australia; Australians who travel do so at their own responsibility, and nothing here is medical advice.

If this article raises difficult feelings for you, support is available from Lifeline on 13 11 14.